These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 8133048

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment.
    Haggerty HG, Warner WA, Comereski CR, Peden WM, Mezza LE, Damle BD, Siegall CB, Davidson TJ.
    Toxicol Pathol; 1999; 27(1):87-94. PubMed ID: 10367679
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
    Henry CJ, Buss MS, Hellström I, Hellström KE, Brewer WG, Bryan JN, Siegall CB.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):751-5. PubMed ID: 15701865
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
    Pai LH, Batra JK, FitzGerald DJ, Willingham MC, Pastan I.
    Cancer Res; 1992 Jun 01; 52(11):3189-93. PubMed ID: 1591729
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs.
    Siegall CB, Liggitt D, Chace D, Mixan B, Sugai J, Davidson T, Steinitz M.
    Clin Cancer Res; 1997 Mar 01; 3(3):339-45. PubMed ID: 9815690
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen.
    Francisco JA, Gilliland LK, Stebbins MR, Norris NA, Ledbetter JA, Siegall CB.
    Cancer Res; 1995 Jul 15; 55(14):3099-104. PubMed ID: 7541711
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40.
    Siegall CB.
    Recent Results Cancer Res; 1996 Jul 15; 140():51-60. PubMed ID: 8787077
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40.
    Francisco JA, Schreiber GJ, Comereski CR, Mezza LE, Warner GL, Davidson TJ, Ledbetter JA, Siegall CB.
    Blood; 1997 Jun 15; 89(12):4493-500. PubMed ID: 9192773
    [Abstract] [Full Text] [Related]

  • 17. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.
    Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellström I, Hellström KE.
    Science; 1993 Jul 09; 261(5118):212-5. PubMed ID: 8327892
    [Abstract] [Full Text] [Related]

  • 18. A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells.
    Akamatsu Y, Murphy JC, Nolan KF, Thomas P, Kreitman RJ, Leung SO, Junghans RP.
    Clin Cancer Res; 1998 Nov 09; 4(11):2825-32. PubMed ID: 9829749
    [Abstract] [Full Text] [Related]

  • 19. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
    Sjögren HO, Isaksson M, Willner D, Hellström I, Hellström KE, Trail PA.
    Cancer Res; 1997 Oct 15; 57(20):4530-6. PubMed ID: 9377565
    [Abstract] [Full Text] [Related]

  • 20. Development of an immunoassay for BMS-191352, a single-chain immunotoxin, and its application to toxicokinetic studies.
    Damle B, Hollenbaugh D, Timoszyk J, Tay L, Kaul S.
    J Immunoassay; 1998 Oct 15; 19(2-3):145-65. PubMed ID: 9682129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.